The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway

Ruixin Liu; Dingxie Liu; Eliana Trink; Ermal Bojdani; Guang Ning; Mingzhao Xing

首页> 外文期刊>The journal of clinical endocrinology and metabolism >The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway

【24h】

The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway

机译：特异性抑制剂MK2206选择性地抑制含有可以激活PI3K / AKT途径的突变的甲状腺癌细胞

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Context:The phosphoinositide 3-kinase (PI3K)/Akt pathway is widely postulated to be an effective therapeutic target in thyroid cancer.

机译：背景：磷酸阳性3-激酶（PI3K）/ AKT途径被广泛假设是甲状腺癌中的有效治疗靶标。

著录项

来源
《The journal of clinical endocrinology and metabolism》 |2011年第4期|共9页
作者
Ruixin Liu; Dingxie Liu; Eliana Trink; Ermal Bojdani; Guang Ning; Mingzhao Xing;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600E Inhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells [J] . Ruixin Liu, Dingxie Liu, Mingzhao Xing The journal of clinical endocrinology and metabolism . 2012,第2期

机译：Akt抑制剂MK2206在抑制甲状腺癌细胞方面协同作用，但Perifosine拮抗BRAFV600E抑制剂PLX4032和MEK1 / 2抑制剂AZD6244。
2. Activation of WNT/beta-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations [J] . Park Ye-Lim, Kim Hwang-Phill, Cho Young-Won, International Journal of Cancer =: Journal International du Cancer . 2019,第2期

机译：激活WNT /β-连环蛋白信号传导导致含PIK3CA突变的结肠直肠癌细胞中双PI3K / MTOR抑制剂的抗性
3. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. [J] . Serra V, Markman B, Scaltriti M, Cancer research: The official organ of the American Association for Cancer Research, Inc . 2008,第19期

机译：NVP-BEZ235是一种PI3K / mTOR双重抑制剂，可防止PI3K信号传导并通过激活PI3K突变来抑制癌细胞的生长。
4. M2-A, A Novel Amonafide Analogue, Induces Apoptosis and G2-M Arrest via Decreasing Topoisomerase LIa Activity and Inhibits PI3K/Akt Pathway on HL60 Cells [C] . The 12th Asian Pacific Confederation of Chemical Engineering Congress(第十二届亚太化工联盟大会暨化工展览会)论文集 . 2008

机译：M2-A，一种新颖的阿莫那肽类似物，通过降低拓扑异构酶LIa活性诱导HL60细胞凋亡和G2-M逮捕并抑制PI3K / Akt途径。
5. The multi-targeted receptor tyrosine kinase inhibitor, linifanib (ABT-869), induces apoptosis and inhibits proliferation of leukemia cells through phosphoinositide-3 kinase (PI3K)/AKT-dependent signaling pathways. [D] . Hernandez, Jenny Elizabeth. 2010

机译：多靶点受体酪氨酸激酶抑制剂利尼法尼（ABT-869）通过磷酸肌醇3激酶（PI3K）/ AKT依赖性信号传导途径诱导凋亡并抑制白血病细胞的增殖。
6. The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway [O] . Ruixin Liu, Dingxie Liu, Eliana Trink, -1

机译：Akt特异性抑制剂MK2206选择性抑制携带可激活PI3K / Akt途径的突变的甲状腺癌细胞。
7. The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway [O] . Liu, Ruixin, Liu, Dingxie, Trink, Eliana, 2011

机译：Akt特异性抑制剂MK2206选择性抑制携带可激活PI3K / Akt途径的突变的甲状腺癌细胞。

The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway

摘要

著录项

相似文献

相关主题

期刊订阅